表达SARS-CoV-2刺突蛋白的腺病毒疫苗鼻内接种改善小鼠模型疫苗免疫
研究在小鼠模型中比较鼻内与肌内接种表达SARS-CoV-2刺突蛋白的腺病毒载体疫苗的免疫效果。单剂鼻内Ad5-RBD或Ad5-S可诱导血清和BAL中抗刺突IgA/IgG、中和活性及T细胞免疫,并保护小鼠抵御β变异株攻击;肌内接种不诱导BAL IgA且血清中和滴度较低。鼻内Ad5-S加强可增强既往mRNA疫苗免疫并转向黏膜IgA应答;鼻内接种后未在肝脾检出Ad5 DNA。
要点
- 单剂鼻内Ad5-RBD或Ad5-S诱导血清和BAL抗刺突IgA/IgG及中和活性。
- 鼻内接种保护小鼠抵御SARS-CoV-2 β变异株攻击,肌内接种不诱导BAL IgA。
- 鼻内Ad5-S加强可增强既往肌内mRNA疫苗免疫并调节为黏膜IgA应答。
核心结论
- 鼻内接种表达SARS-CoV-2刺突蛋白的腺病毒疫苗在小鼠模型中可诱导黏膜免疫并保护抵御β变异株攻击,支持该途径用于预防SARS-CoV-2传播的潜力。
研究设计与样本
- 研究在小鼠模型(包括HLA class II人源化转基因品系)中开展一系列实验,比较鼻内与肌内接种表达SARS-CoV-2刺突蛋白受体结合域(Ad5-RBD)或完整外域(Ad5-S)的5型腺病毒载体疫苗的免疫效果。
主要发现
- 单剂鼻内Ad5-RBD或Ad5-S诱导血清和支气管肺泡灌洗液(BAL)抗刺突IgA和IgG、血清和BAL中强效SARS-CoV-2中和活性、强烈的刺突特异性Th1/细胞毒性T细胞免疫,并保护小鼠抵御SARS-CoV-2 β变异株攻击。
- 肌内接种Ad5-RBD或Ad5-S不诱导血清或BAL IgA,且血清中和滴度较低。
- 既往肌内mRNA疫苗诱导的免疫可被鼻内Ad5-S加强剂有效增强并调节为黏膜IgA应答。
- 肌内接种后可在肝脏或脾脏检出Ad5 DNA,鼻内接种后未检出,提示疫苗载体缺乏全身播散。
- 在HLA-DQ8小鼠中Ad5-RBD疫苗劣于Ad5-S,而在遗传背景相同的HLA-DQ6小鼠中未见此差异,提示RBD片段不含足够的辅助T细胞表位以构成最佳疫苗抗原。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The ongoing SARS-CoV-2 pandemic is controlled but not halted by public health measures and mass vaccination strategies which have exclusively relied on intramuscular vaccines. Intranasal vaccines can prime or recruit to the respiratory epithelium mucosal immune cells capable of preventing infection. Here we report a comprehensive series of studies on this concept using various mouse models, including HLA class II-humanized transgenic strains. We found that a single intranasal (i.n.) dose of serotype-5 adenoviral vectors expressing either the receptor binding domain (Ad5-RBD) or the complete ectodomain (Ad5-S) of the SARS-CoV-2 spike protein was effective in inducing i) serum and bronchoalveolar lavage (BAL) anti-spike IgA and IgG, ii) robust SARS-CoV-2-neutralizing activity in the serum and BAL, iii) rigorous spike-directed T helper 1 cell/cytotoxic T cell immunity, and iv) protection of mice from a challenge with the SARS-CoV-2 beta variant. Intramuscular (i.m.) Ad5-RBD or Ad5-S administration did not induce serum or BAL IgA, and resulted in lower neutralizing titers in the serum. Moreover, prior immunity induced by an intramuscular mRNA vaccine could be potently enhanced and modulated towards a mucosal IgA response by an i.n. Ad5-S booster. Notably, Ad5 DNA was found in the liver or spleen after i.m. but not i.n. administration, indicating a lack of systemic spread of the vaccine vector, which has been associated with a risk of thrombotic thrombocytopenia. Unlike in otherwise genetically identical HLA-DQ6 mice, in HLA-DQ8 mice Ad5-RBD vaccine was inferior to Ad5-S, suggesting that the RBD fragment does not contain a sufficient collection of helper-T cell epitopes to constitute an optimal vaccine antigen. Our data add to previous promising preclinical results on intranasal SARS-CoV-2 vaccination and support the potential of this approach to elicit mucosal immunity for preventing transmission of SARS-CoV-2.
引用
- Freitag TL, Fagerlund R, Karam NL, et al. Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models. Vaccine. 2023. PMID: 37085458. doi:10.1016/j.vaccine.2023.04.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。